CIBC Private Wealth Group
BPMC

CIBC Private Wealth Group’s Blueprint Medicines BPMC Stock Holding History

CIBC Private Wealth Group’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4
Closed -$513 – 3116
2025
Q2 		$513 Buy
+4
New +$415 ﹤0.01% 2835

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

CIBC Private Wealth Group's BPMC Position: Q3 2025 in Review

CIBC Private Wealth Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 4 shares — an estimated $513 sold.

CIBC Private Wealth Group first reported a position in BPMC in Q2 2025 and held it in 1 quarter. The position peaked at $513 in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • CIBC Private Wealth Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 4 Blueprint Medicines shares in Q3 2025, an estimated $513.
  • CIBC Private Wealth Group first reported a position in Blueprint Medicines in Q2 2025 and held it in 1 quarter.
  • CIBC Private Wealth Group's Blueprint Medicines position peaked at $513 in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on CIBC Private Wealth Group's 13F filing for Q3 2025, filed 24 Nov 2025.